Novo resumes Wegovy 1.7 mg supply; GSK’s £200M manufacturing expansion in the UK; SmartLabs’ $48M Series C

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

No­vo Nordisk re­sumed ship­ments of We­govy 1.7 mg dose ear­li­er this month, which had been pre­vi­ous­ly out of stock in the US in mid-De­cem­ber, a spokesper­son told End­points. “De­mand con­tin­ues to out­pace our in­creas­ing pro­duc­tion of We­govy. As a re­sult, we an­tic­i­pate po­ten­tial for on­go­ing sup­ply dis­rup­tions, and some pa­tients may con­tin­ue hav­ing dif­fi­cul­ty fill­ing We­govy pre­scrip­tions,” the spokesper­son added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.